Amarin Corp Plcuk (AMRN) Depreciation and Depletion (2015 - 2016)
Amarin Corp Plcuk (AMRN) posted quarterly Depreciation and Depletion of -$14000.0 for Q4 2016, down 118.67% YoY from $75000.0 in Q1 2016, and down 140.0% sequentially from $35000.0 in Q3 2016.
Amarin Corp Plcuk (AMRN) Depreciation and Depletion (2015 - 2016) Analysis & Trends
Amarin Corp Plcuk has disclosed Depreciation and Depletion across 2 years of filings, most recently posting -$14000.0 for Q4 2016.
- In Q4 2016, Depreciation and Depletion fell 118.67% year-over-year to -$14000.0; the TTM figure through Dec 2016 stood at $136000.0 (changed N/A YoY), while the FY2025 annual figure was $100000.0, changed 0.0% from the prior year.
- Depreciation and Depletion declined to -$14000.0 in Q4 2016, from $35000.0 in the prior quarter.
- Over the last five years, Depreciation and Depletion for AMRN reached as high as $75000.0 in Q4 2015 and fell as low as -$14000.0 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 188.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 581.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 93.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | -14,000.00 |
| Dec 31, 2016 | -14,000.00 |
| Sep 30, 2016 | 35,000.00 |
| Sep 30, 2016 | 35,000.00 |
| Dec 31, 2015 | 75,000.00 |
| Dec 31, 2015 | 75,000.00 |
| Sep 30, 2015 | 40,000.00 |
| Sep 30, 2015 | 40,000.00 |